AGIO
insider transactionsAGIOS PHARMACEUTICALS, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-34.6K
0 buy · 34.6K sell
Net value · 90d
-$1.2M
$0 in · $1.2M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
7
0 buy · 34.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director
$0
2.0K sh
Own New
-
Exercise·M
Director
$0
2.0K sh
Own +33%
-
Exercise·M
Director
$0
2.0K sh
Own New
-
Exercise·M
Director
$0
2.0K sh
Own +33%
-
Exercise·M
Chief Legal Officer · 10b5-1
$0
8.5K sh
Own New
-
Sell·S
Chief Legal Officer · 10b5-1
$113.8K
3.3K sh · $34.71
Own -6%
-
Exercise·M
Chief Legal Officer · 10b5-1
$0
8.5K sh
Own +19%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
8.5K sh
Own New
-
Sell·S
Chief Medical Officer · 10b5-1
$102.0K
2.9K sh · $34.71
Own -4%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
8.5K sh
Own +11%
-
Exercise·M
Cecilia Jones KEY
Chief Financial Officer · 10b5-1
$0
8.5K sh
Own New
-
Sell·S
Cecilia Jones KEY
Chief Financial Officer · 10b5-1
$109.0K
3.1K sh · $34.71
Own -5%
-
Exercise·M
Cecilia Jones KEY
Chief Financial Officer · 10b5-1
$0
8.5K sh
Own +17%
-
Exercise·M
Chief Commercial Officer · 10b5-1
$0
8.5K sh
Own New
-
Sell·S
Chief Commercial Officer · 10b5-1
$113.2K
3.3K sh · $34.71
Own -7%
-
Exercise·M
Chief Commercial Officer · 10b5-1
$0
8.5K sh
Own +20%
-
Exercise·M
Chief Corp Dev & Strategy · 10b5-1
$0
8.1K sh
Own New
-
Sell·S
Chief Corp Dev & Strategy · 10b5-1
$102.7K
3.0K sh · $34.71
Own -22%
-
Exercise·M
Chief Corp Dev & Strategy · 10b5-1
$0
8.1K sh
Own +158%
-
Exercise·M
Brian Goff KEY
Chief Executive Officer · 10b5-1
$0
13.5K sh
Own +50%
-
Exercise·M
Brian Goff KEY
Chief Executive Officer · 10b5-1
$0
25.5K sh
Own New
-
Sell·S
Brian Goff KEY
Chief Executive Officer · 10b5-1
$228.9K
6.6K sh · $34.71
Own -3%
-
Exercise·M
Brian Goff KEY
Chief Executive Officer · 10b5-1
$0
13.5K sh
Own +8%
-
Sell·S
Brian Goff KEY
Chief Executive Officer · 10b5-1
$432.9K
12.5K sh · $34.71
Own -7%
-
Exercise·M
Brian Goff KEY
Chief Executive Officer · 10b5-1
$0
25.5K sh
Own +16%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 13, 2026 | Adams Catherine Owen | Exercise M | 2.0K | $0 |
| Jun 13, 2026 | Adams Catherine Owen | Exercise M | 2.0K | $0 |
| Jun 13, 2026 | Jeffrey D Capello | Exercise M | 2.0K | $0 |
| Jun 13, 2026 | Jeffrey D Capello | Exercise M | 2.0K | $0 |
| Apr 2, 2026 | James William Burns 10b5-1 | Exercise M | 8.5K | $0 |
| Apr 2, 2026 | James William Burns 10b5-1 | Sell S | 3.3K | $113.8K |
| Apr 2, 2026 | James William Burns 10b5-1 | Exercise M | 8.5K | $0 |
| Apr 2, 2026 | Sarah Gheuens 10b5-1 | Exercise M | 8.5K | $0 |
| Apr 2, 2026 | Sarah Gheuens 10b5-1 | Sell S | 2.9K | $102.0K |
| Apr 2, 2026 | Sarah Gheuens 10b5-1 | Exercise M | 8.5K | $0 |
| Apr 2, 2026 | Cecilia Jones KEY 10b5-1 | Exercise M | 8.5K | $0 |
| Apr 2, 2026 | Cecilia Jones KEY 10b5-1 | Sell S | 3.1K | $109.0K |
| Apr 2, 2026 | Cecilia Jones KEY 10b5-1 | Exercise M | 8.5K | $0 |
| Apr 2, 2026 | Tsveta Milanova 10b5-1 | Exercise M | 8.5K | $0 |
| Apr 2, 2026 | Tsveta Milanova 10b5-1 | Sell S | 3.3K | $113.2K |
| Apr 2, 2026 | Tsveta Milanova 10b5-1 | Exercise M | 8.5K | $0 |
| Apr 2, 2026 | Krishnan Viswanadhan 10b5-1 | Exercise M | 8.1K | $0 |
| Apr 2, 2026 | Krishnan Viswanadhan 10b5-1 | Sell S | 3.0K | $102.7K |
| Apr 2, 2026 | Krishnan Viswanadhan 10b5-1 | Exercise M | 8.1K | $0 |
| Apr 2, 2026 | Brian Goff KEY 10b5-1 | Exercise M | 13.5K | $0 |
| Apr 2, 2026 | Brian Goff KEY 10b5-1 | Exercise M | 25.5K | $0 |
| Apr 2, 2026 | Brian Goff KEY 10b5-1 | Sell S | 6.6K | $228.9K |
| Apr 2, 2026 | Brian Goff KEY 10b5-1 | Exercise M | 13.5K | $0 |
| Apr 2, 2026 | Brian Goff KEY 10b5-1 | Sell S | 12.5K | $432.9K |
| Apr 2, 2026 | Brian Goff KEY 10b5-1 | Exercise M | 25.5K | $0 |
About AGIO insider trading
This page tracks insider transactions for AGIOS PHARMACEUTICALS, INC. (AGIO) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.